The past decade has witnessed a surge in the demand for active pharmaceutical ingredients (APIs). Alfa Chemistry responds quickly to such a fact and launches an integrated platform with small molecule APIs/intermediates development and manufacturing capabilities from preclinical to commercial stages.
Together with the previously launched 9 popular APIs that are readily-available, including dexmedetomidine hydrochloride, donepezil, lenalidomide, parecoxib sodium, rivaroxaban, tofacitinib citrate, tamoxifen citrate, epalrestat and edaravone, Alfa Chemistry is now well-positioned to help move forward customers’ projects in a faster pace for drug developers worldwide.
“As a research-driven and customer-based company, we’re committed to help our clients shorten their time for drug development and lower the cost of drug manufacturing. We enable customers to benefit from our tailored methods that balance their needs in terms of speed and cost,” says the Marketing Chief of Alfa Chemistry. “Our strength lies in the expertise of our synthetic group. With smart choice of the most appropriate chemical technologies and with our state-of-the-art Pharmaceutical manufacturing facilities, we believe the synthesis process would be robust and highly efficient.”
Now a broad spectrum of API research and development services are available at Alfa Chemistry, which covers: synthetic route development, process development and optimization, scale up, registration and validation batch manufacture, and commercial supply production.
Different quantities of APIs and advanced intermediates, ranging from grams to kilograms, can be produced. To accomplish an API research and development project better and faster, modern tools such as automated workstations, statistical software, and reaction calorimetry will also be utilized. Please visit the website https://www.alfa-chemistry.com/services/api-research-development.html to learn more about Alfa Chemistry’s capabilities as a CRO.
About Active Pharmaceutical Ingredient
All drugs are generally made up of two core components—the API and the excipient. The former is the part of any drug that produces the intended effects. In combination therapies, drugs have multiple active ingredients to treat different symptoms or act in different ways.
Production of APIs has traditionally been done by the pharmaceutical companies themselves. But in recent years many corporations have opted to outsource manufacturing for the purpose of cutting costs. Owing to years of efforts, the market-oriented and customer-centered chemical vendor Alfa Chemistry has established good cooperation relationships with many pharmaceutical companies, universities and research institutions. It now ushers in its new role as a Contract Research Organization, offering tailored solutions for pharmaceutical companies in their attempt to API Research & Development.